Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medgenics Inc Prices Public Offering Of Common Stock And Warrants


Friday, 8 Feb 2013 02:00am EST 

Medgenics Inc announced that it has priced an underwritten public offering of 5,600,000 shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2,800,000 shares of common stock at an initial exercise price of $6.78. The shares and the warrants will be sold together as a fixed combination, each consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, at a price to the public of $5.25 per fixed combination. The shares of common stock and warrants will be issued separately. Gross proceeds to Medgenics will be $29,400,000. The offering is expected to close on February 13, 2013. Maxim Group LLC is acting as sole book-running manager for the offering. National Securities Corporation and MLV & Co. are acting as co-managers for the offering. Nomura Code Securities Limited and SVS Securities Plc acted as sub-agents to the offering in Europe. Medgenics has granted the underwriters a 45-day option to purchase up to an aggregate of 840,000 additional shares of common stock and/or additional warrants to purchase up to an aggregate of 420,000 shares of common stock. 

Company Quote

6.65
-0.06 -0.89%
21 Jul 2014